DUBLIN, June 13, 2023 /PRNewswire/ — The “Minimal Residual Disease Testing Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the market.
The global minimal residual disease testing market is expected to grow from $1.22 billion in 2022 to $1.41 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The minimal residual disease testing market is expected to reach $2.32 billion in 2027 at a CAGR of 13.3%.
Major players in the minimal residual disease testing market are Natera Inc., Guardant Health, Laboratory Corporation of America Holdings, QIAGEN N.V, F. Hoffmann-La Roche Ltd, Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC., Veracyte Inc., Cergentis B.V, Mdxhealth, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers, and PerkinElmer Inc.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Minimal residual disease testing refers to a very sensitive test to detect cancer cells in the patient’s body that may remain after treatment. It is used to monitor the effectiveness of cancer treatment and inform future treatment strategies.
The main test types of minimal residual disease testing are DNA – based tests, RNA- based tests, and immunological tests. DNA (deoxyribonucleic acid)-based testing (also known as genetic testing) is a type of medical examination that can spot changes to your chromosomes, genes, or proteins. The various technologies include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, are used in various applications such as haematological malignancies, leukemia, lymphoma, solid tumors, and others. These are used by hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and others.
The minimal residual disease testing market research report is one of a series of new reports that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Product innovations are a key trend gaining popularity in the minimal residual disease testing market. Major companies operating in the minimal residual disease testing market are innovating new products to sustain their position in the market.
For instance, in 2022, Twist Bioscience, a US-based synthetic biology and genomics company, launched Twist MRD Panel to advance research and development in minimal residual disease (MRD) detection in cancer screening. Twist MRD Panel is a customizable panel of genes that can be used to detect very low levels of residual cancer cells in a patient’s blood. The Twist MRD Panel is designed to be highly flexible and customizable that can be integrated into a typical next-generation sequencing (NGS) workflow that can find minimum residual disease (MRD) in just five days.
North America was the largest region in the minimal residual disease testing market in 2022. The regions covered in minimal residual disease testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease testing market going forward. Cancer refers to a condition when a few of the body’s cells grow out of control and spread to other bodily regions. Cancer stages are primarily detected through minimal residual disease testing, which is a very sensitive method to detect cancer cells in the human body. It helps cancer patients prevent the disease at an early stage, boosting the minimal residual disease testing market.
For instance, in February 2022, according to the reports shared by the World Health Organization (WHO), a Switzerland-based health agency, cancer will be the most common cause of death worldwide. In 2020, according to the World Cancer Fund Research International, a UK-based a not-for-profit association related to cancer prevention, there were 18,094,716 million new cases of cancer worldwide. Additionally, in 2020, globally, nearly 10 million people died due to cancer, which is nearly one in six deaths. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease testing market.
The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Key Topics Covered:
1. Executive Summary
2. Minimal Residual Disease Testing Market Characteristics
3. Minimal Residual Disease Testing Market Trends And Strategies
4. Minimal Residual Disease Testing Market – Macro Economic Scenario
4.1. COVID-19 Impact On Minimal Residual Disease Testing Market
4.2. Ukraine-Russia War Impact On Minimal Residual Disease Testing Market
4.3. Impact Of High Inflation On Minimal Residual Disease Testing Market
5. Minimal Residual Disease Testing Market Size And Growth
5.1. Global Minimal Residual Disease Testing Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Minimal Residual Disease Testing Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Minimal Residual Disease Testing Market Segmentation
6.1. Global Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- DNA – Based Test
- RNA- Based Test
- Immunological Test
6.2. Global Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other Technologies
6.3. Global Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Other Application
6.4. Global Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Hospitals And Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Other End Users
7. Minimal Residual Disease Testing Market Regional And Country Analysis
7.1. Global Minimal Residual Disease Testing Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Minimal Residual Disease Testing Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/y2fxf8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
